Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety and efficacy of luspatercept for beta-thalassemia has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia

Drugs mentioned

• Luspatercept (luspatercept)

Snippet

Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Conditions: B-Thalassemia | Phase 2 | Status: COMPLETED | Results posted: 2024-07-18